Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$39.16 - $88.71 $1.77 Million - $4.01 Million
-45,205 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$75.82 - $150.97 $744,476 - $1.48 Million
-9,819 Reduced 17.84%
45,205 $3.72 Million
Q4 2021

Feb 14, 2022

BUY
$132.01 - $190.29 $7.26 Million - $10.5 Million
55,024 New
55,024 $8.07 Million

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track First Light Asset Management, LLC Portfolio

Follow First Light Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Light Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on First Light Asset Management, LLC with notifications on news.